October 19, 2026

Tempus Presents Data Demonstrating AI-Enabled Pre-Screening Can Help Identify Patients for Biomarker Testing in NSCLC

Tempus: Study presented at ESMO evaluated more than 60,000 advanced NSCLC cases and found greater than 80% sensitivity across all 12 biomarkers using routine H&E pathology images CHICAGO--(BUSINESS WIRE)--Tempus AI, Inc. (NASDAQ: TEM) today...

recent articles

International panel of pathologists drive forward-thinking agenda on role of pathology in transforming cancer diagnostics and improve patient care London, UK –Nov. 13, 2019–– On International Pathology Day, Leica Biosystems, a...

Recognized for disrupting 150-year-old practice of pathology with artificial intelligence to improve cancer patient outcomes Proscia, a leading provider of digital pathology software, has been named to the CNBC Upstart 100, an exclusive...

~ Creating mutually beneficial partnership with distributors to strengthen sales channel in US, Europe, Africa and Asia ~ San Jose, CA, November 13th, 2019: OptraSCAN®, the leading on-demand digital pathology solution provider today...

Sale of respected laboratory information system company may be an early sign that investors believe clinical laboratories and pathology groups are ready to upgrade their LISs and add needed capabilities In the past 10 years there has been...

Join Proscia for two webinars this month on how to more easily manage massive, multi-site studies with digital pathology. Planning and Executing Studies with Whole Slide Imaging Tuesday, November 12 at 12PM ET To better integrate whole...

CE Mark enables Proscia’s entry into international anatomic pathology market Philadelphia – November 6, 2019 – Proscia, a leading provider of digital pathology software, has received a CE Mark for its Concentriq Dx solution for use in...

OR

platinum partners

gold partners

Silver Partners

Media Partners